Hepatitis C Antiviral Treatment (DAA) — free guideline decision tool
This tool gives the HCV direct-acting-antiviral regimen direction by cirrhosis status and pregnancy, with pre-treatment assessment and the SVR12 endpoint.
Open guideline tool →Guideline-based
Implements the decision logic from published clinical guidelines.
Runs in your browser
No installation. Enter the patient's values and get a guideline recommendation instantly.
Data stays local
Nothing is uploaded. Results are for licensed clinicians only.
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| Cirrhosis status | No cirrhosis |
|---|---|
| Pregnancy | Yes |
→DispositionDefer DAA in pregnancy
- Note：DAAs are not recommended in pregnancy; antiviral treatment can be given after delivery and the end of breastfeeding. Women of childbearing potential should be screened for pregnancy before treatment and avoid pregnancy during treatment
- Principle：All HCV RNA–positive individuals should receive antiviral treatment at an appropriate time, with the endpoint of SVR12
- Basis：Guideline for the Prevention and Treatment of Hepatitis C (2022 edition)
| Cirrhosis status | Decompensated cirrhosis (Child B/C or prior decompensation) |
|---|---|
| Pregnancy | No |
→Regimen directionSOF/VEL + RBV 12 weeks
- Indication：All HCV RNA–positive individuals should receive antiviral treatment (with very few exceptions of very short life expectancy)
- Recommended regimen：Decompensated: protease inhibitors (e.g. glecaprevir/pibrentasvir) contraindicated; use sofosbuvir/velpatasvir + ribavirin for 12 weeks (RBV contraindicated → no combination, extend to 24 weeks)
- Pre-treatment assessment：Liver disease severity (cirrhosis/decompensation), renal function, quantitative HCV RNA, HBsAg, comorbidities and drug-drug interactions; genotyping may be omitted with a pangenotypic regimen where local 3b prevalence < 5%
Common questions
What is Hepatitis C Antiviral Treatment (DAA)?
This tool gives the HCV direct-acting-antiviral regimen direction by cirrhosis status and pregnancy, with pre-treatment assessment and the SVR12 endpoint.
How is Hepatitis C Antiviral Treatment (DAA) calculated? What is the core formula?
No cirrhosis/compensated → SOF/VEL 12 weeks or GLE/PIB 8 weeks. Decompensated → protease inhibitors contraindicated, SOF/VEL + RBV 12 weeks. Pregnant → defer. Endpoint SVR12.
When is Hepatitis C Antiviral Treatment (DAA) used?
Use to choose a pangenotypic regimen in non-cirrhotic/compensated disease, a specialist SOF/VEL + RBV regimen in decompensation, and to defer therapy in pregnancy.
What are the key clinical points for Hepatitis C Antiviral Treatment (DAA)?
Protease-inhibitor regimens are contraindicated in decompensated cirrhosis, which is managed by hepatology with SOF/VEL + ribavirin. (original synthesis · not guideline verbatim) Pre-treatment HBsAg screening prevents HBV reactivation during DAA therapy. Cirrhotic patients continue HCC surveillance even after achieving SVR.
What are the limits and cautions when using Hepatitis C Antiviral Treatment (DAA)?
For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
How is Hepatitis C Antiviral Treatment (DAA) calculated in practice? Can you show a worked example?
Inputs: Cirrhosis status No cirrhosis, Pregnancy Yes → Result: Disposition Defer DAA in pregnancy（Note: DAAs are not recommended in pregnancy; antiviral treatment can be given after delivery and the end of breastfeeding. Women of childbearing potential should be screened for pregnancy before treatment and avoid pregnancy during treatment, Principle: All HCV RNA–positive individuals should receive antiviral treatment at an appropriate time, with the endpoint of SVR12, Basis: Guideline for the Prevention and Treatment of Hepatitis C (2022 edition)） Inputs: Cirrhosis status Decompensated cirrhosis (Child B/C or prior decompensation), Pregnancy No → Result: Regimen direction SOF/VEL + RBV 12 weeks（Indication: All HCV RNA–positive individuals should receive antiviral treatment (with very few exceptions of very short life expectancy), Recommended regimen: Decompensated: protease inhibitors (e.g. glecaprevir/pibrentasvir) contraindicated; use sofosbuvir/velpatasvir + ribavirin for 12 weeks (RBV contraindicated → no combination, extend to 24 weeks), Pre-treatment assessment: Liver disease severity (cirrhosis/decompensation), renal function, quantitative HCV RNA, HBsAg, comorbidities and drug-drug interactions; genotyping may be omitted with a pangenotypic regimen where local 3b prevalence < 5%）
Run Hepatitis C Antiviral Treatment (DAA) now
This tool gives the HCV direct-acting-antiviral regimen direction by cirrhosis status and pregnancy, with pre-treatment assessment and the SVR12 endpoint.
Open guideline tool →For licensed clinicians. Not a substitute for clinical judgement.
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.